Evidence map›Paper›PMID 41704346›Full record

ArticleACS medicinal chemistry letters2026

Potent, Selective Pyrrolopyrimidine PDE11A4 Inhibitors with Improved Pharmaceutical Properties.

Shams Ul Mahmood, Rama Krishna Boddu, Jeremy Eberhard, Charles S Hoffman, John Gordon, Dennis Colussi, Wayne Childers, Elvis Amurrio, Marie Danaher, Michy P Kelly and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Shams Ul MahmoodDepartment of Chemistry and Biochemistry, Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, New Jersey 07043, United States.
Rama Krishna BodduDepartment of Chemistry and Biochemistry, Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, New Jersey 07043, United States.
Jeremy EberhardBiology Department, Boston College, Chestnut Hill, Massachusetts 02467, United States.
Charles S HoffmanBiology Department, Boston College, Chestnut Hill, Massachusetts 02467, United States.
John GordonMoulder Center for Drug Discovery, Temple University, Philadelphia, Pennsylvania 19140, United States.
Dennis ColussiMoulder Center for Drug Discovery, Temple University, Philadelphia, Pennsylvania 19140, United States.
Wayne ChildersMoulder Center for Drug Discovery, Temple University, Philadelphia, Pennsylvania 19140, United States.
Elvis AmurrioDepartment of Neurobiology, University of Maryland School of Medicine, Center for Research on Aging, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Marie DanaherDepartment of Neurobiology, University of Maryland School of Medicine, Center for Research on Aging, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Michy P KellyDepartment of Neurobiology, University of Maryland School of Medicine, Center for Research on Aging, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
David P RotellaDepartment of Chemistry and Biochemistry, Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, New Jersey 07043, United States.ORCID https://orcid.org/0000-0002-8224-218X

Funding

Pharmacologic Inhibition of PDE11A for Age-Related Memory DisordersR01AG067836 · NIA · MONTCLAIR STATE UNIVERSITY · PI HOFFMAN, CHARLES S., KELLY, MICHY PATRICE · 2020 to 2024
$3.6M
NIA NIH HHS R01 AG067836
6 · The paper itself

Abstract

Previous work demonstrated target engagement with an orally bioavailable, potent, selective PDE11A4 inhibitor in the mouse hypothalamus. This compound was limited by low aqueous solubility, stimulating the need for alternative leads with improved pharmaceutical properties to carry out efficacy studies. This paper outlines optimization of a pyrrolopyrimidine hit leading to a potent, selective PDE11A4 inhibitor with improved pharmaceutical properties and promising activity in cell-based models of enzyme activity.

Indexed as

cell-based activityLLPS activityPDE11A4pharmaceutical propertiesphosphodiesterase inhibitor

Identifiers

PMID41704346
PMCPMC12907953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.